Nonsteroidal anti-inflammatory drugs in primary care – pain therapy Review article
Article Sidebar
Published:
Jun 30, 2025
Keywords:
pain, therapy, nonsteroidal anti-inflammatory drugs
Main Article Content
Abstract
Pain is a subjective experience associated with actual or potential tissue damage. Among the most commonly used pharmaceuticals in pain therapy are nonsteroidal anti-inflammatory drugs (NSAIDs), which belong to the first step of the analgesic ladder. NSAIDs are not a homogeneous group of drugs – one of their distinguishing features is their selectivity in inhibiting COX-2, which is responsible for their anti-inflammatory, analgesic, antipyretic, and antithrombotic effects. This article discusses the mechanism of action, therapeutic indications, and limitations of NSAIDs in pain therapy.
Article Details
How to Cite
Sapilak, B. J. (2025). Nonsteroidal anti-inflammatory drugs in primary care – pain therapy. Medycyna Faktow (J EBM), 18(2(67), 211-215. https://doi.org/10.24292/01.MF.0225.07
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
2. Brune K, Patrigiani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015; 8: 105-18.
3. Arkinstall W, Sandler A, Groughnour B et al. Efficacy of controlledrelease codeine in chronic non-malignant pain: a randomized, placebo controlled trial. Pain. 1995; 62: 178-96.
4. Kocot-Kępska M, Szułdrzyński K. Skale oceny bólu. https://www.mp.pl/bol/wytyczne/91404,skale-oceny-bolu.
5. Brown TJ, Hooper L, Elliott RA et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modeling. Health Technol Assess. 2006; 10: iii-iv, xi-xiii, 1-183.
6. Rell K. Wybrane aspekty bezpieczeństwa leczenia niesteroidowymi lekami przeciwzapalnymi w świetle ostatnich doniesień. Lekarz POZ. 2019; 3–4: 313-21.
7. Kołłątaj M, Wordliczek J, Dobrogowski J et al. McGill Pain Questionnaire and its short form. BÓL. 2013; 14(3): 10-3.
2. Brune K, Patrigiani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015; 8: 105-18.
3. Arkinstall W, Sandler A, Groughnour B et al. Efficacy of controlledrelease codeine in chronic non-malignant pain: a randomized, placebo controlled trial. Pain. 1995; 62: 178-96.
4. Kocot-Kępska M, Szułdrzyński K. Skale oceny bólu. https://www.mp.pl/bol/wytyczne/91404,skale-oceny-bolu.
5. Brown TJ, Hooper L, Elliott RA et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modeling. Health Technol Assess. 2006; 10: iii-iv, xi-xiii, 1-183.
6. Rell K. Wybrane aspekty bezpieczeństwa leczenia niesteroidowymi lekami przeciwzapalnymi w świetle ostatnich doniesień. Lekarz POZ. 2019; 3–4: 313-21.
7. Kołłątaj M, Wordliczek J, Dobrogowski J et al. McGill Pain Questionnaire and its short form. BÓL. 2013; 14(3): 10-3.